
    
      A Phase I, open-label, randomized, two way crossover pharmacokinetic study comparing the
      bioavailability of acetylsalicylic acid (ASA) after 5 days repeated once daily administration
      of a fixed dose combination capsule of ASA 81 mg/esomeprazole 20 mg and ASA 80 mg (European
      aspirin reference product).
    
  